Seattle Genetics, Inc. is pleased to inform you that on April 17, 2020, the FDA approved TUKYSA tablets for oral administrationTUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Please see attached full Prescribing Information HERE

Below is the product information needed to load TUKYSA.

NDC

51144-002-60

TUKYSA

(tucatinib) 150mg

Yellow, caplet-shaped tablet

TUC embossed on one side, 150 on other side

60 count tablets/bottle

NDC

51144-001-60

TUKYSA

(tucatinib) 50mg

Yellow, round-convex tablet

TUC embossed on one side, 50 on other side

60 count tablets/bottle

TUKYSA can be ordered through the following Specialty Distributors:

ASD Healthcare

McKesson Plasma & Biologics

Cardinal Health

McKesson Specialty Health

Oncology Supply

Click here to learn more.

Read More

In light of the developing situation around COVID-19, we would like to share immediate action Bristol Myers Squibb is taking to support the health and well-being of patients, customers and employees during this time. Bristol Myers Squibb is expanding its longstanding patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic. The expanded program offers access to BMS medicine for free. Read more here or download patient-support-program-overview

 

Read More